
Recognition of sepsis ‘urgent and persistent safety risk'
The Health Services Safety Investigations Body (HSSIB) said that the 'recognition of sepsis remains an urgent and persistent safety risk'.
It comes as the watchdog examined three cases where patients suffered severe harm or death as a result of sepsis not being diagnosed soon enough.
Sepsis is a life-threatening reaction to an infection that occurs when the immune system overreacts and starts to damage the body's tissues and organs.
In the UK, 245,000 people are affected by sepsis every year.
The three cases described in HSSIB's latest reports include:
– An elderly man named as Ged, who had a urine infection. Ged died from sepsis after his antibiotics were not given to him for almost 20 hours due to difficulties lining up GP out-of-hours systems and those of his nursing home.
– A grandmother called Lorna, who died from sepsis after being admitted to an acute assessment unit after attending a hospital with abdominal pain. HSSIB said that doctors on the AAU 'did not always have the capacity to review patients in person' and that it was only when she was seen by a doctor some hours later her sepsis was recognised.
– A woman named Barbara, who had diabetes and a foot infection, which led to sepsis. She survived her ordeal but needed to have her leg amputated below the knee to 'gain control' of the infection. Concerns were raised that she should have been transferred to a second hospital sooner and whether this would have avoided her developing sepsis and the need for such extensive amputation. She spent four months in hospital.
HSSIB said that the reports also highlight how family members are not always listened to when expressing concerns about a loved one's condition deteriorating.
It said the reports reiterate the difficulty of diagnosing sepsis in its early stages.
Melanie Ottewill, senior safety investigator at HSSIB, said: 'These reports show a consistent pattern of issues around the early recognition and treatment of sepsis.
'The experiences of Barbara, Ged and Lorna show the devastating consequences of sepsis.
'They also highlight the imperative of listening to families when they express concerns about their loved one and tell us about changes in how they are.
'The distress caused by not feeling heard significantly compounded the grief of Ged's and Lorna's families.
'The trauma of their loss was deeply felt throughout their involvement in our investigation.
'Each report contains detailed analysis and practical insights, offering a significant body of learning for improving patient safety and conducting effective investigations.'
Commenting on the reports, Dr Ron Daniels, founder of the UK Sepsis Trust, said: 'These reports provide a valuable reiteration of how quickly sepsis can develop – and therefore how swift diagnosis and treatment must be – as well as a reminder of why it's so important to maintain consistent awareness of every sepsis symptom.
'It's critical too that members of the public feel empowered to act as advocates when their loved ones are unwell, and that healthcare professionals take them seriously.
'We also need a commitment from health ministers on the development and implementation of a 'sepsis pathway' – a standardised treatment plan that ensures patients receive the right care from the point at which they present their symptoms to a clinician through to receiving their diagnosis.
'By responding effectively and reliably to sepsis, our health service can save lives and improve outcomes for the thousands of people affected by this condition every year.'
An NHS England spokesperson said: 'NHS staff work extremely hard to keep patients safe and NHS England has supported the implementation of Early Warning Systems to improve recognition and response for all causes of deterioration, including sepsis.
'The introduction of Martha's Rule and the routine use of patient wellness questionnaires is also helping patients and their families to alert staff to subtle changes in how patients are feeling – potentially identifying early signs of deterioration – while giving them the right to call for an urgent review if they remain concerned about a patient getting worse.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
11 minutes ago
- Reuters
Focus: To stay on weight-loss drugs, US patients cut doses and maybe vacations
Aug 13 (Reuters) - Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but as more U.S. insurers restrict coverage people are trimming costs by stretching doses or forgoing expenditures like vacations to pay for the medication out of pocket. A half dozen doctors who spoke with Reuters said insurance coverage has tightened in 2025 as many employers drop it for the expensive GLP-1 drugs. While patients on these medications are counseled on proper diet and exercise, clinical trials show that people who stop taking these drugs are apt to regain weight, opens new tab. Novo Nordisk's ( opens new tab Wegovy and Eli Lilly's (LLY.N), opens new tab Zepbound are weekly injections with U.S. insurer list prices of more than $1,000 a month. For customers willing to pay cash, both drugmakers will ship directly for $499 a month if refills are purchased at fixed intervals. "A significant number of my patients now pay cash," said Dr. Nidhi Kansal, an obesity specialist at Northwestern Medicine in Chicago. "People find a way to scrounge up $6,000 a year, which sucks, because that's a vacation or two." More than a billion people worldwide are obese, according to the U.N. World Health Organization, which has said the GLP-1 drugs could help end the obesity pandemic. A tech industry job change for Yelena Kibasova, a 40-year-old who lives in the Minneapolis area, meant loss of coverage for her Zepbound prescription that helped her achieve and maintain a 150-pound (68-kg) weight loss. "My new company does not cover GLP-1s, so now I am in a kind of purgatory," Kibasova said. "I stopped doing my nails. I stopped doing my hair. Those things are not as important as me staying at a healthy weight." The doctors interviewed by Reuters said patients once leery about long-term obesity treatment are now more comfortable staying on a drug. The doctors said that conversations about temporary use happen only when a patient is trying to lose a certain amount of weight for issues such as fertility treatment or an organ transplant. These obesity specialists said they are hopeful that competition will help bring down prices as new weight-loss options emerge, including new oral drugs that may be available next year. Lilly last week announced trial results for its easier-to-manufacture pill, which was shown to cut patient weight by 12.4%, a few percentage points less than injected drugs. The company hopes to launch it in August 2026. Kenneth Custer, Lilly's head of cardiometabolic health, told Reuters the pill is being tested in several settings, including as a maintenance therapy. Custer declined to comment on how it might be priced. Dr. Anne Peters, an endocrinologist at Keck Medicine USC in Los Angeles, said it is important that patients who reach their weight-loss goal not stop a prescription "cold turkey," so the dose can be tapered down over several months. Peters said about a third of her patients are able to reduce their dose and maintain weight loss, while the rest need to stay on the medication. An analysis of U.S. pharmacy insurance claims found that nearly two-thirds of patients who started on Wegovy or Zepbound in 2024 were still on the medications a year later. Peters said she uses "every technique in the book" to secure insurance coverage for patients, but noted that a growing number of plans no longer pay for the treatments, and patients have to pay out-of-pocket. U.S. pharmacies supply self-injection pens pre-loaded with doses of Wegovy or Zepbound. Lilly's direct-to-consumer service also offers vials. "Some patients can stretch out the vials longer. Get 15 mg, and then give a 10 mg dose for instance," Dr. Peters said, noting that the drug's instructions advise that such an approach should not be taken. Doses of 5 mg, 10 mg and 15 mg are recommended for weight-loss maintenance. Patients also are turning to lower-cost compounded versions of the GLP-1 drugs, or are even mixing them at home with raw ingredients, both of which Peters and other doctors advise against due to safety concerns. Dr. Angela Fitch, former president of the Centennial, Colorado-based Obesity Medicine Association and chief medical officer at online primary care provider Knownwell, said nobody wants to be on a medication, but patients who respond to a GLP-1 drug "really don't want to go off of it when they recognize that it has such a value to them." Both Wegovy and Zepbound were first launched, under the brand names Ozempic and Mounjaro, as diabetes treatments. The class has been linked to a range of benefits, including improved heart health and less sleep apnea. Fitch said the most common reason for her patients to stop taking a GLP-1 drug is loss of insurance coverage. She said her experience is that about 10% of patients are able to reach a target weight and maintain it without further treatment. "We are in a dip where people are dropping coverage," Fitch said, adding that the direct-to-consumer options are an "upper-ish middle-class thing."


Daily Mail
39 minutes ago
- Daily Mail
Welsh Rugby Union chief executive Abi Tierney to take leave of absence from role after health diagnosis
Welsh Rugby Union chief executive Abi Tierney is to temporarily step away from her role to undergo treatment for cancer. Tierney's diagnosis means health, understandably, is her top priority. WRU chair Richard Collier-Keywood and director of rugby Dave Reddin will step up to lead the organisation. They will do so at a crucial time for the game in Wales with a decision on a likely reduction of the number of the country's domestic teams set to be made in the coming months. Tierney's time away from the WRU will begin from August 22. 'This has not been an easy decision, but it is one I must make to focus fully on my health and recovery,' she said. 'I am grateful for the support I have already received from my family, friends and colleagues and I am confident in the team's ability to continue our work during my absence. I kindly ask for understanding and privacy during this time.' Tierney had been leading the imminent consultation period over the future of the professional game in Wales – one which is set to define how Welsh rugby looks moving forward. As such, she steps away at a key time. However, her decision is entirely the right one. Collier-Keywood said: 'I, together with the whole of the board and everyone involved with Welsh rugby, wish Abi well over this period. 'The WRU is committed to supporting her during this time. 'In my role as chair, I will continue to have overall responsibility for the WRU and in order to provide cover and give Abi the space she needs, will be more involved in the immediate future. 'Abi and the board have recruited a strong executive team which will continue to lead the WRU on a day-to-day basis. 'The most important topic on our agenda right now is the consultation on the future of elite rugby in Wales. 'This will be led by our director of rugby and elite performance Dave Reddin as a member of the executive and I will take overall responsibility for its successful delivery.'


The Herald Scotland
39 minutes ago
- The Herald Scotland
Aberdeen University study to probe link between anorexia and autism
Researchers from the University of Aberdeen are seeking volunteers from the autistic community to undergo a brain scan with the aim of better understanding the relationship between brain structure, eating disorder symptoms and autistic 'masking' behaviour. Masking is a behaviour exhibited by autistic individuals, where specific behaviours are consciously or unconsciously concealed to fit into social situations normally, or to avoid negative responses from others. However, masking, particularly as a long-term strategy, can produce negative effects on autistic people's mental health and well-being. Concerns have been raised about the effectiveness and potential harms of traditional eating disorder treatments for the autistic community, leading to calls to develop new autistic-affirming approaches to eating disorder treatments. Aberdeen University (Image: NQ) Autistic individuals who have a current or past diagnosis of anorexia nervosa, or those who have no history of an eating disorder, are needed for the pioneering study which hopes to provide insights which can be used to better tailor future treatments. The study is being carried out and supervised by Dr Michelle Sader who is postdoctoral research fellow for the Eating Disorders and Autism Collaborative (EDAC) at the University of Aberdeen. EDAC is a UK-wide collaborative network seeking to bridge the gap between autism and eating disorders research through a lived experience lens. Dr Sader said: 'In our previous work, autistic collaborators highlighted the importance of investigating how masking behaviour relates to eating disorder development or maintenance in autistic people. 'Taking part in this research would not only help us understand what regions of the brain may be associated with autistic masking, but also whether masking is differently associated with, or plays a different role in autistic individuals with an eating disorder. Dr Sader added: 'Around 27 per cent of autistic people display symptoms of eating disorders, and individuals with more autistic characteristics tend to experience more severe eating disorder symptoms. 'There is a significant overlap between autism and eating disorders which is not yet fully understood, and we need to change that. 'By taking part, volunteers will be helping shape a future with more appropriate and effective support for autistic individuals.'